THE MANAGEMENT OF PATIENTS WITH GAUCHER DISEASE, TYPE 1

<p>Background. Accumulation of glucocerebroside in spleen, liver, bone marrow and bones, but rarely in other organs, due to inborn deficiency of lisosomal enzyme glucocerebrosidase leads to Gaucher disease. The most common is type 1, chronic non-neuronopathic form of Gaucher disease. In type 1...

Full description

Bibliographic Details
Main Authors: Majda Benedik-Dolničar, Lidija Kitanovski
Format: Article
Language:English
Published: Slovenian Medical Association 2003-12-01
Series:Zdravniški Vestnik
Subjects:
Online Access:http://vestnik.szd.si/index.php/ZdravVest/article/view/1895
id doaj-a94fe07ab180400fa3b090be892737de
record_format Article
spelling doaj-a94fe07ab180400fa3b090be892737de2020-11-24T22:57:42ZengSlovenian Medical AssociationZdravniški Vestnik1318-03471581-02242003-12-0172121396THE MANAGEMENT OF PATIENTS WITH GAUCHER DISEASE, TYPE 1Majda Benedik-Dolničar0Lidija Kitanovski1Služba za onkologijo in hematologijo Pediatrična klinika Klinični center Vrazov trg 1 1525 LjubljanaSlužba za onkologijo in hematologijo Pediatrična klinika Klinični center Vrazov trg 1 1525 Ljubljana<p>Background. Accumulation of glucocerebroside in spleen, liver, bone marrow and bones, but rarely in other organs, due to inborn deficiency of lisosomal enzyme glucocerebrosidase leads to Gaucher disease. The most common is type 1, chronic non-neuronopathic form of Gaucher disease. In type 1 the central nervous system is not affected and clinical presentations are variable. It could be a mild disease not necessitating therapy or a more severe one which sometimes results even in disability. In such cases the replacement enzyme therapy is reasonable and the dose should be adjusted to the severity of the illness. It improves the patient’s condition and prevents the progression of the disease.</p><p>Conclusions. This article emphasises the guidelines for the management of patients with Gaucher disease, type 1. Recommendations for diagnostic approach and follow up of the patients as well as groups of patients necessitating a replacement enzyme therapy at appropriate doses are defined and stated.<br /><br /></p>http://vestnik.szd.si/index.php/ZdravVest/article/view/1895Gaucherguidelinesmanagementdiagnostictreatment
collection DOAJ
language English
format Article
sources DOAJ
author Majda Benedik-Dolničar
Lidija Kitanovski
spellingShingle Majda Benedik-Dolničar
Lidija Kitanovski
THE MANAGEMENT OF PATIENTS WITH GAUCHER DISEASE, TYPE 1
Zdravniški Vestnik
Gaucher
guidelines
management
diagnostic
treatment
author_facet Majda Benedik-Dolničar
Lidija Kitanovski
author_sort Majda Benedik-Dolničar
title THE MANAGEMENT OF PATIENTS WITH GAUCHER DISEASE, TYPE 1
title_short THE MANAGEMENT OF PATIENTS WITH GAUCHER DISEASE, TYPE 1
title_full THE MANAGEMENT OF PATIENTS WITH GAUCHER DISEASE, TYPE 1
title_fullStr THE MANAGEMENT OF PATIENTS WITH GAUCHER DISEASE, TYPE 1
title_full_unstemmed THE MANAGEMENT OF PATIENTS WITH GAUCHER DISEASE, TYPE 1
title_sort management of patients with gaucher disease, type 1
publisher Slovenian Medical Association
series Zdravniški Vestnik
issn 1318-0347
1581-0224
publishDate 2003-12-01
description <p>Background. Accumulation of glucocerebroside in spleen, liver, bone marrow and bones, but rarely in other organs, due to inborn deficiency of lisosomal enzyme glucocerebrosidase leads to Gaucher disease. The most common is type 1, chronic non-neuronopathic form of Gaucher disease. In type 1 the central nervous system is not affected and clinical presentations are variable. It could be a mild disease not necessitating therapy or a more severe one which sometimes results even in disability. In such cases the replacement enzyme therapy is reasonable and the dose should be adjusted to the severity of the illness. It improves the patient’s condition and prevents the progression of the disease.</p><p>Conclusions. This article emphasises the guidelines for the management of patients with Gaucher disease, type 1. Recommendations for diagnostic approach and follow up of the patients as well as groups of patients necessitating a replacement enzyme therapy at appropriate doses are defined and stated.<br /><br /></p>
topic Gaucher
guidelines
management
diagnostic
treatment
url http://vestnik.szd.si/index.php/ZdravVest/article/view/1895
work_keys_str_mv AT majdabenedikdolnicar themanagementofpatientswithgaucherdiseasetype1
AT lidijakitanovski themanagementofpatientswithgaucherdiseasetype1
AT majdabenedikdolnicar managementofpatientswithgaucherdiseasetype1
AT lidijakitanovski managementofpatientswithgaucherdiseasetype1
_version_ 1725649665548877824